Clinical trial allows Abrazo Arizona to offer heart surgery alternative to low-risk patients
< img src="http://media.bizj.us/view/img/10093991/azheart-tavr-181931*100xx1501-1500-94-0.jpg" > As part of a nationwide clinical trial, Abrazo Arizona Heart Hospital will begin performing procedures on low-risk patients with complex heart conditions that would serve as an alternative to open-heart surgery.
The hospital will be the first in Arizona to perform Transcatheter Aortic Valve Replacement (TAVR) procedures on low-risk patients suffering from aortic stenosis. Abrazo is one of 80 hospitals around the nation participating in the five-year-long clinic trial.
“This is a very innovative… < div class="feedflare" >...
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 21, 2016 Category: Pharmaceuticals Authors: Becca Smouse Source Type: news
‘Strikingly’ low 1-year mortality recorded for TAVR device
Findings from the PARTNER trial of the SAPIEN3 transcatheter heart valve system support the use of transcatheter aortic valve replacement as “the preferred therapy” in high-risk and inoperable patients with aortic stenosis. (Source: MedWire News)
Source: MedWire News - July 14, 2016 Category: Consumer Health News Tags: Interventional cardiology Source Type: news
Possible Cancer Finding on Pre-TAVR CT Doesn't Affect SurvivalPossible Cancer Finding on Pre-TAVR CT Doesn't Affect Survival
"The presence of malignancy may not necessarily be a contraindication to TAVR, since the life-limiting condition may be the aortic stenosis," said one expert. Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 1, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news
One-third of patients with low flow aortic stenosis do not improve with transcatheter aortic valve replacement, research finds
For patients with low flow aortic stenosis, TAVR -- a minimally invasive procedure which corrects the damaged aortic valve -- is often the best option for restoring the heart's normal pumping function. However, approximately one-third of these patients treated with TAVR continue to suffer persistent low flow AS. Researchers have examined this high-risk patient population to determine the cause and evaluate risk of mortality. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 15, 2016 Category: Science Source Type: news
TAVI, SAVR Outcomes Not Significantly Different in Short TermTAVI, SAVR Outcomes Not Significantly Different in Short Term
Early and midterm outcomes of transcatheter aortic valve implantation (TAVI) are not significantly different from those of surgical aortic valve replacement (SAVR) in patients treated for severe aortic stenosis, according to a new meta-analysis. Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - June 10, 2016 Category: Surgery Tags: General Surgery News Source Type: news
TAVI matches SAVR for early and midterm mortality
Transcatheter aortic valve implantation has similar early and midterm mortality to surgical aortic valve replacement in patients with aortic stenosis, including those at low to intermediate risk, show results of a systematic review and meta-analysis. (Source: MedWire News)
Source: MedWire News - June 8, 2016 Category: Consumer Health News Tags: Interventional cardiology Source Type: news
Should TAVR Be Performed in Nonagenarians?Should TAVR Be Performed in Nonagenarians?
An increasing number of nonagenarians present with severe aortic stenosis. Can they benefit from transcatheter aortic valve replacement? Journal of the American College of Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 2, 2016 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
CoreValve High-Risk Study at 3 Years: TAVR Advantage SustainedCoreValve High-Risk Study at 3 Years: TAVR Advantage Sustained
In this high-risk population with severe aortic stenosis, patients were less likely to die or have a stroke within 3 years if they had percutaneous rather than surgical valve replacement. Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 15, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news
Edwards Lifesciences hits all-time high on Sapien 3 study
Shares in Edwards Lifesciences (NYSE:EW) hit an all-time high yesterday after the company reported strong 1-year data for its Sapien 3 replacement heart valve over the weekend.
Results from the Partner II trial from 1,077 intermediate-risk patients showed that the Sapien 3 beat surgical valve replacement across a variety of safety endpoints, Irvine, Calif.-based Edwards said at the American College of Cardiology’s annual meeting April 3. The combined all-cause death & disabling stroke rate was 8.4% for TAVR with Sapien 3 and 16.6% for the surgery arm, according to the study, which was also published in The Lan...
Source: Mass Device - April 5, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Replacement Heart Valves Wall Street Beat American College of Cardiology Conference (ACC) Edwards Lifesciences Source Type: news
Edwards Lifesciences touts intermediate-risk data for Sapien devices | ACC 2016
Data from a large trial of the Sapien line of replacement heart valves made by Edwards Lifesciences (NYSE:EW) are slated to be used to back bids for expanded indications in intermediate-risk patients.
Presented over the weekend at the American College of Cardiology’s annual meeting in Chicago, results from the Partner II trial involving the Sapien XT and Sapien 3 transcatheter aortic valve replacements compared the TAVR treatments with traditional open surgery in the intermediate-risk cohort (both of the Edwards valves are already approved in the U.S. for high-risk patients).
Sapien XT non-inferior to surgery at 2...
Source: Mass Device - April 4, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Replacement Heart Valves American College of Cardiology Conference (ACC) Edwards Lifesciences Source Type: news
Rates of death and stroke equivalent for surgery and TAVR at two years
Intermediate-risk patients with severe aortic stenosis who receive minimally invasive transcatheter aortic valve replacement, known as TAVR, have similar rates of death and disabling strokes after two years compared with those undergoing standard open heart surgical replacement, according to a new study. Patients receiving TAVR also experienced shorter hospital stays and lower incidence of some major complications compared with those undergoing surgery. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 3, 2016 Category: Science Source Type: news
Medtronic CoreValve ® System Demonstrates Superior Survival to Surgery in Aortic Stenosis Patients with Lower STS Scores
The analysis of the sub-cohort compared 202 patients treated with the CoreValve System against 181 patients who received surgical aortic valve replacement (SAVR). The CoreValve TAVR patients demonstrated superior outcomes in all-cause mortality at two years compared to patients treated with surgical aortic valve replacement (15.0 percent vs. 26.3 percent; p=0.01). In addition, rates of combined all-cause mortality or major stroke were superior for TAVR with the CoreValve System (17.1 percent vs. 31.9 percent; p=0.0018). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - April 3, 2016 Category: Cardiology Source Type: news
Medtronic CoreValve® System Demonstrates Superior Survival to Surgery in Aortic Stenosis Patients with Lower STS Scores
The analysis of the sub-cohort compared 202 patients treated with the CoreValve System against 181 patients who received surgical aortic valve replacement (SAVR). The CoreValve TAVR patients demonstrated superior outcomes in all-cause mortality at two years compared to patients treated with surgical aortic valve replacement (15.0 percent vs. 26.3 percent; p=0.01). In addition, rates of combined all-cause mortality or major stroke were superior for TAVR with the CoreValve System (17.1 percent vs. 31.9 percent; p=0.0018). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - April 3, 2016 Category: Cardiology Source Type: news
First Patients Enrolled in Medtronic Trial in Low-Risk Aortic Stenosis Patients
Medtronic plc (NYSE: MDT) today announced that the first patients were enrolled in the expanded indication trial for the CoreValve® Evolut® R System, the first and only next-generation recapturable, self-expanding transcatheter aortic valve replacement (TAVR) system commercially available in the United States. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - April 1, 2016 Category: Cardiology Source Type: news
Post-TAVR Mortality Lower in Women
Women undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis have lower 1-year mortality than men, even though their 30-day rates of vascular complications and major bleeding are worse, according to a report published in Annals of Internal Medicine. (Source: Caring for the Ages)
Source: Caring for the Ages - March 30, 2016 Category: Health Management Authors: Mary Ann Moon Source Type: news
